Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors

• Published in: Oncology letters Vol. 17; no. 3; pp. 3517 - 3522
• Main Authors: Jia, Xiaotian, Chen, Chao, Chen, Lin, Yu, Cong, Kondo, Tadashi
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.03.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Acids; Biological markers; Biomarkers; Care and treatment; Chemotherapy; Chromatography; Development and progression; Disease; EDTA; Ethics; Gene expression; Genetic aspects; Glycoproteins; Health aspects; Immunohistochemistry; Mass spectrometry; Medical prognosis; Metastasis; Nervous system tumors; Oncology; Orthopedic surgery; Peptides; Proteomics; Radiation therapy; Sarcoma; Scientific imaging; Spectroscopy; Studies; Surgery; Tumors; prognostic biomarker; label-free quantitative proteomics; malignant peripheral nerve sheath tumor; formalin-fixed paraffin-embedded; decorin
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2019.9959

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas. The prognosis of MPNSTs has been reported to differ among previous studies. However, there have been a number of reported prognostic biomarkers associated with MPNSTs. In the present study, a proteomics study was performed to discover the differential protein expression in patients with MPSNTs with different prognoses. The clinical data of 30 primary extremities of patients with MPNSTs, who underwent surgery at the Department of Hand Surgery, Huashan Hospital, Fudan University between January 2002 and December 2011, were acquired. A total of 16 patients succumbed to their diseases within 5 years, whereas 14 patients were disease-free for >5 years. Samples from the 9 patients who succumbed within 2 years were assigned to Group D, while samples from the 8 patients who were continuously disease-free for >5 years following diagnosis were assigned to Group L for the proteomics study. Label-free quantitative proteomics and mass spectrometry were performed to filtrate differential protein in patients with MPSNTs with different prognoses. Decorin was filtrated as a differential protein of note. The expression level of decorin was significantly lower in Group D compared with that in Group L (D/L=0.0948; P=0.0004). The result was verified by immunohistochemical staining in the 30 primary extremities of patients with MPNSTs. The 5-year survival rate of patients with positive expression of decorin was 78.57%, while the 5-year survival rate of patients negative for decorin expression was 18.75% (P=0.0014). Overall, a high level of decorin indicted a better prognosis in patients with MPNSTs. With further investigation, decorin may be a reliable prognostic biomarker for MPNSTs.